Pfizer's latest phase 3 trial results put its promising eczema drug on a path to challenge Regeneron and Sanofi's $2 billion-per-year drug, Dupixent. Also, how Regenxbio and Adverum Biotechnologies hope to change how a we treat a common cause of vision loss in seniors, and why United Healthcare's latest quarterly results sent shares soaring. Check out more of our content here:  TMF's podcast portal YouTube Twitter Join Our Motley Fool Podcast Facebook Group LinkedIn  StockUp, The Motley Fool's weekly email newsletter 

Healthcare: Pfizer Takes Aim At Regeneron, And UnitedHealth's Earnings Update

Healthcare, technology, energy, consumer goods, and more. Every day, Motley Fool analysts break down a specific industry and the stocks making headlines. Questions? Comments? Email us at IndustryFocus@fool.com.

Business

Investing

Careers

Management & Marketing

Business News

Shopping

News

We're moving over to a new show! Here's a sneak peek of what to expect when Motley Fool Money goes daily on January 5, 2022.  Subscribe here on Spotify Subscribe here on  Apple Podcasts 

Introducing the New Motley Fool Money

Nick, Emily, Jason, and Dylan get together to talk through the companies they've learned the most from, the stocks they've sold recently (and why!) and also where you can catch all of them with The Motley Fool's new audio offering in 2022. Stocks: MELI, SHOP, GME, BBY Check out more of our content here: Podcasts  Youtube Twitter Reach us by Email @ IndustryFocus@fool.com

Wildcard: The Stocks We've Learned the Most From

In this last iteration of Industry Focus Consumer Goods (don’t worry - we’re just moving to Motley Fool Money!), Emily Flippen and Asit Sharma revisit their 2021 consumer goods basket as well as reflect on lessons learned from investing in the industry at large. Stocks: Grocery Outlet (GO), Peloton (PTON), Beyond Meat (BYND), Dollar General (DG), and Sleep Number (SNBR) Check out more of our content here: Podcasts  Youtube Twitter Reach us by Email @ IndustryFocus@fool.com

CG: The Long Goodbye

On this week’s episode of Industry Focus: Financials host Jason Moser sits down with Motley Fool contributor Dan Caplinger. Tune in as they discuss why regulators are taking a closer look at the buy now pay later space. Then they wrap up the show with a listener question on where to put non-stock portfolio cash. Check out more of our content here: Podcasts  Youtube Twitter Reach us by Email @ IndustryFocus@fool.com

Financials: Regulators Take a Closer Look at Buy Now Pay Later

We revisit all the new companies we talked about in 2021, look at the landscape of the IPO market in general, and zoom in on some of the most interesting debuts from the year. Stocks: OLO, KNBE, GLBE Listener survey: https://www.foolinsights.com/se/04BD76CC18830996 Check out more of our content here: Podcasts  Youtube Twitter Reach us by Email @ IndustryFocus@fool.com

Healthcare: Pfizer Takes Aim At Regeneron, And UnitedHealth's Earnings Update

Download our free app to listen on your phone